PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY-COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN

被引：1
|
作者：
Quinzler, R. [1 ]
Ude, M. [2 ]
Franzmann, A. [1 ]
Feldt, S. [1 ]
Leuner, K. [2 ]
Mueller, W. E. [2 ]
Dippel, F. W. [3 ]
Schulz, M. [4 ]
机构：
[1] German Inst Drug Use Evaluat DAPI, GIDE, Eschborn, Hessen, Germany
[2] Goethe Univ Frankfurt, Frankfurt, Hessen, Germany
[3] Sanofi Aventis, Berlin, Germany
[4] ABDA Fed Union German Assoc Pharmacists, Berlin, Germany
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74141-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A234 / A234
页数：1
相关论文
共 50 条
  • [31] Insulin glargine: Basal insulin of choice?
    Chen, SW
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (07) : 609 - 609
  • [32] Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
    Pfohl, Martin
    Siegmund, Thorsten
    Pscherer, Stefan
    Pegelow, Katrin
    Seufert, Jochen
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 569 - 578
  • [33] Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
    Ginsberg, Henry
    Cariou, Bertrand
    Orchard, Trevor
    Chen, Lei
    Luo, Junxiang
    Bastyr, Edward J., III
    Bue-Valleskey, Juliana
    Chang, Annette M.
    Ivanyi, Tibor
    Jacober, Scott J.
    Hoogwerf, Byron J.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (11): : 1089 - 1092
  • [34] A Comparison of CV-FBG in T2DM with Use of Glargine/NPH as a Basal Insulin
    Mu Pan-Wei
    Zeng Long-Yi
    Zhang Guo-Chao
    Chen Yan-Ming
    Fu Jing-Yi
    Wang Man-Man
    [J]. DIABETES, 2010, 59 : A174 - A174
  • [35] Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients
    Pfeiffer, C
    Winkler, F
    Luger, A
    Pieber, T
    Saudek, F
    Skrha, J
    Hermansen, K
    Lervang, HH
    Nistrup-Holmegaard, S
    Bergkulla, S
    Lembcke, HJ
    Schulze, J
    Petersen, KG
    Haslbeck, M
    Jonker, JJC
    Vaaler, S
    Rolstad, OJ
    Distiller, LA
    Robertson, LI
    Omar, MAK
    Wing, J
    Arner, P
    Arnqvist, H
    Lager, I
    Lennerhagen, P
    Borthwick, LJ
    Hattersley, A
    Owens, DR
    Matthews, DR
    Nattrass, M
    [J]. DIABETIC MEDICINE, 2003, 20 (07) : 545 - 551
  • [36] Insulin therapy in type 2 diabetes: A prospective 18 month comparison of insulin glargine and NPH insulin in patients with a multiple injection regimen
    Siegmund, T
    Born, T
    Weber, S
    Usadel, KH
    Schumm-Draeger, PM
    [J]. DIABETES, 2003, 52 : A456 - A456
  • [37] Lower severe hypoglycemia risk: Insulin glargine versus NPH insulin in type 2 diabetes
    Dailey, George
    Strange, Poul
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (01): : 25 - 30
  • [38] Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies
    Duckworth, William
    Davis, Stephen N.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 196 - 204
  • [39] Comparison of insulin Glargine (HOE901) vs NPH insulin during 1 year of insulin combination therapy in type 2 diabetes
    Yki-Jarvinen, H
    Dressler, A
    Zieman, M
    [J]. DIABETES, 2000, 49 : A130 - A131
  • [40] Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with type 2 diabetes
    Luzio, SD
    Beck, P
    Owens, DR
    [J]. HORMONE AND METABOLIC RESEARCH, 2003, 35 (07) : 434 - 438
12345